Table 3.
Baseline and change from baseline in QTc by correction method and by study treatment.
| Treatment | QTcF (ms) | QTcB (ms) | QTcSS (ms) |
|---|---|---|---|
| Baseline | |||
| DHA-PQP | 384.3 (21.0) | 422.9 (21.3) | 415.5 (21.1) |
| PA | 383.0 (21.4) | 419.2 (20.3) | 411.8 (20.6) |
| ASAQ | 384.4 (20.8) | 423.2 (20.8) | 415.5 (20.4) |
| AL | 383.1 (21.0) | 421.7 (22.0) | 414.3 (21.4) |
| Change from baseline | |||
| DHA-PQP | 31.3 (29.7; 32.8) | 16.3 (14.8; 17.9) | 19.4 (17.9; 21.0) |
| PA | 9.2 (7.8; 10.6) | −3.7 (−5.1; −2.3) | −0.8 (−2.2; 0.6) |
| ASAQ | 30.9 (29.0; 32.7) | 12.5 (10.5; 14.5) | 16.2 (14.3; 18.1) |
| AL | 18.8 (29.0; 32.7) | 1.8 (−0.1; 3.6) | 5.2 (3.4; 7.0) |
Data are expressed as mean (SD for baseline and 90% confidence interval for change from baseline). DHA-PQP, dihydroartemisinin-piperaquine; PA, pyronaridine-artesunate; ASAQ, artesunate-amodiaquine; AL, artemether-lumefantrine.